Home 2023

Archives

Figure 1: Immunomodulatory therapies are effective during the relapsing-remitting phase of MS, when immune cells are found in active lesions, but fail to ameliorate progressive decline and irreversible clinical disability. Increased axonal injury correlates with lack of immune cell infiltration but sustained activation of resident CNS glial cells in the progressive phase. These pathological findings are consistent with MRI imaging studies demonstrating virtually no new lesions occurring during progressive MS. Additionally, at the time of MS diagnosis there is evidence of prior lesion activity by MRI imaging supporting that the future development of neuroprotective strategies should be administered in combination with immunomodulatory therapies.

Targeting the central nervous system: The future of therapeutic strategies for MS

Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, looks at the future of therapeutic strategies for MS, focusing on targeting the central nervous system.
prevent MS, CT scan

Great leaps in multiple sclerosis treatment but the holy grail is still ahead

CEO of MS Australia Rohan Greenland highlights the breakthroughs in treating attacks on the brain and spinal cord in multiple sclerosis (MS). But his sights are set firmly on the great unmet needs: to repair damaged nerves, reverse disability, and ultimately, prevent MS.

Remyelinating versus neuroprotective therapies for multiple sclerosis

Reducing clinical relapses and improving quality of life is at the heart of MS treatment; here Tara M. DeSilva explores the benefits of remyelinating versus neuroprotective therapies for tackling MS.

Follow Us

Advertisements

Open Access Government

Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.

Follow Us

Resources

Quick Links

Legal & Marketing

As a Crossref Sponsored Member we are able to connect your content with a global network of online scholarly research, currently over 20,000 other organizational members from 160 countries. Crossref drive metadata exchange and support nearly 2 billion monthly API queries, facilitating global research communication.

© Adjacent Digital Politics Ltd